This study is checking the safety of a medicine called Resmetirom (MGL-3196) for people with Non-alcoholic Fatty Liver Disease (NAFLD). NAFLD is when too much fat is stored in liver cells. The study is for 52 weeks, and participants will take the medicine once a day. It's an open-label study, which means everyone knows they're getting the medicine.
Who Can Join:
- If you finished a previous study called MAESTRO-NAFLD-1 or tried to join MAESTRO-NASH but didn't qualify, you might be able to join.
- You need to have had certain liver tests, like a biopsy, and meet specific results.
- If you have cirrhosis (scarring of the liver) but are otherwise stable, you might qualify.
Who Cannot Join:
- If you've had too much alcohol recently or have liver cancer, you cannot join.
- Other liver diseases or autoimmune diseases also make you ineligible.
Key Points:
- The study lasts about one year with daily medicine intake.
- You must have completed or attempted to join specific earlier studies.
- People with certain health issues or risks cannot join.
How understandable was the trial content above?
Hard to understand
Easy to understand